Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncolytic viral immunotherapies designed to generate durable anti-tumor immune responses in patients with cancer. The company operates within the biotechnology and oncology therapeutics industries, with an emphasis on genetically engineered viral platforms intended to work both as direct cancer cell killers and immune system activators.
Candel’s primary value driver is its Adenovirus and HSV-based viral platforms, most notably its lead product candidate CAN‑2409, which is being evaluated across multiple solid tumor indications including prostate cancer, non–small cell lung cancer, and pancreatic ductal adenocarcinoma. The company targets oncology patients with high unmet medical need and positions its therapies to be used in combination with standard-of-care treatments such as immune checkpoint inhibitors. Candel was founded in 2003 (originally operating as Advantagene, Inc.) and later rebranded to reflect its broader immunotherapy focus, culminating in its public listing on NASDAQ in 2021.
Business Operations
Candel operates as a single-reportable-segment biotechnology company, generating no commercial product revenue and focusing primarily on research and development activities. Its core operations center on advancing its clinical pipeline through Phase 2 and Phase 3 trials, supported by internal R&D capabilities and external clinical research organizations. The company’s technology platform is based on genetically modified viral vectors engineered to selectively replicate in tumor cells and stimulate immune activation.
Operations are primarily based in the United States, with clinical trials conducted both domestically and internationally. Candel controls proprietary viral constructs, manufacturing know-how, and intellectual property related to its oncolytic virus platforms. The company has entered into clinical collaborations with large pharmaceutical companies to evaluate its therapies in combination regimens, while remaining independently operated with no commercialized subsidiaries.
Strategic Position & Investments
Candel’s strategy is centered on advancing late-stage clinical development of CAN‑2409 while expanding the potential of its second platform candidate, CAN‑3110, an HSV‑1–based oncolytic virus targeting high-grade glioma. Growth initiatives focus on achieving regulatory approvals in select oncology indications and validating combination use with approved immunotherapies.
The company has invested heavily in clinical trials, manufacturing scale-up, and regulatory engagement rather than acquisitions. Its portfolio remains internally developed, and it has not disclosed material investments in external operating companies. Candel is strategically positioned in the emerging field of oncolytic viral immunotherapy, a niche within immuno-oncology aimed at addressing tumors resistant to existing treatments.
Geographic Footprint
Candel Therapeutics is headquartered in Needham, Massachusetts, and its primary operational footprint is within North America. The company’s executive leadership, research oversight, and corporate functions are based in the United States.
Internationally, Candel maintains a presence through global clinical trial activities, including trial sites in Europe and other regions as required by specific oncology studies. While it does not operate international commercial offices, its clinical and regulatory reach extends across multiple continents through investigator-led and partner-supported trials.
Leadership & Governance
Candel is led by an executive team with experience in biotechnology development, oncology research, and public company governance. The leadership emphasizes a strategy focused on scientific rigor, disciplined capital allocation, and advancing therapies for cancers with limited treatment options. The company operates under a traditional U.S. public-company governance structure with oversight from an independent board of directors.
Key executives include:
- Paul W. Manning, MD, PhD – Chief Executive Officer
- James DeAngelis – Chief Financial Officer
Information regarding additional executive leadership roles and founders is data inconclusive based on available public sources and could not be independently verified with sufficient consistency across reputable disclosures.